S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Closing prices for crude oil, gold and other commodities
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Closing prices for crude oil, gold and other commodities
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Closing prices for crude oil, gold and other commodities
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Closing prices for crude oil, gold and other commodities
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
NASDAQ:URGN

UroGen Pharma - URGN Stock Forecast, Price & News

$8.53
+0.20 (+2.40%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$8.26
$8.65
50-Day Range
$6.18
$9.08
52-Week Range
$4.85
$19.66
Volume
55,035 shs
Average Volume
55,212 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00

UroGen Pharma MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
122.7% Upside
$19.00 Price Target
Short Interest
Bearish
7.65% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.33
Upright™ Environmental Score
News Sentiment
0.49mentions of UroGen Pharma in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.83) to ($3.43) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

URGN stock logo

About UroGen Pharma (NASDAQ:URGN) Stock

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

UroGen Pharma Stock Performance

Shares of UroGen Pharma stock traded up $0.20 during trading hours on Friday, reaching $8.53. The stock had a trading volume of 55,035 shares, compared to its average volume of 55,212. The firm has a 50 day simple moving average of $7.90 and a two-hundred day simple moving average of $7.43. UroGen Pharma has a 1 year low of $4.85 and a 1 year high of $19.66.

UroGen Pharma (NASDAQ:URGN - Get Rating) last posted its earnings results on Tuesday, May 10th. The company reported ($1.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.36) by $0.11. UroGen Pharma had a negative return on equity of 1,491.69% and a negative net margin of 197.16%. The business had revenue of $13.56 million during the quarter, compared to analyst estimates of $15.62 million. Equities analysts anticipate that UroGen Pharma will post -4.83 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Berenberg Bank assumed coverage on UroGen Pharma in a report on Wednesday, April 27th. They issued a "buy" rating and a $20.00 price objective on the stock.

Receive URGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter.

URGN Stock News Headlines

UroGen Pharma Posts Smaller Q1 Loss
UroGen Pharma earnings preview: what Wall Street is expecting
Earnings Outlook For UroGen Pharma
See More Headlines
Receive URGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter.

URGN Company Calendar

Last Earnings
11/15/2021
Today
8/13/2022
Next Earnings (Estimated)
11/21/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:URGN
Fax
N/A
Employees
195
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.00
High Stock Price Forecast
$26.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+122.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-110,820,000.00
Net Margins
-197.16%
Pretax Margin
-206.02%

Debt

Sales & Book Value

Annual Sales
$48.04 million
Book Value
$4.61 per share

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
0.91

Key Executives














URGN Stock - Frequently Asked Questions

Should I buy or sell UroGen Pharma stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UroGen Pharma in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" URGN shares.
View URGN analyst ratings
or view top-rated stocks.

What is UroGen Pharma's stock price forecast for 2022?

3 equities research analysts have issued 12 month price objectives for UroGen Pharma's stock. Their URGN share price forecasts range from $11.00 to $26.00. On average, they predict the company's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 122.7% from the stock's current price.
View analysts price targets for URGN
or view top-rated stocks among Wall Street analysts.

How have URGN shares performed in 2022?

UroGen Pharma's stock was trading at $9.51 at the start of the year. Since then, URGN stock has decreased by 10.3% and is now trading at $8.53.
View the best growth stocks for 2022 here
.

When is UroGen Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our URGN earnings forecast
.

How were UroGen Pharma's earnings last quarter?

UroGen Pharma Ltd. (NASDAQ:URGN) released its earnings results on Monday, November, 15th. The company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($1.26) by $0.09. The business had revenue of $11.35 million for the quarter, compared to analyst estimates of $15.90 million. UroGen Pharma had a negative trailing twelve-month return on equity of 572.49% and a negative net margin of 209.30%. During the same period in the prior year, the company posted ($1.31) EPS.

What other stocks do shareholders of UroGen Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other UroGen Pharma investors own include Sorrento Therapeutics (SRNE), Micron Technology (MU), OPKO Health (OPK), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL), (KITE) (KITE), Syndax Pharmaceuticals (SNDX), AbbVie (ABBV) and Aytu BioPharma (AYTU).

When did UroGen Pharma IPO?

(URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

What is UroGen Pharma's stock symbol?

UroGen Pharma trades on the NASDAQ under the ticker symbol "URGN."

Who are UroGen Pharma's major shareholders?

UroGen Pharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Menora Mivtachim Holdings LTD. (14.11%), Credit Suisse AG (0.00%), Wells Fargo & Company MN (1.87%), ARK Investment Management LLC (1.45%), Cerity Partners LLC (0.60%) and Rice Hall James & Associates LLC (0.53%). Insiders that own company stock include Elizabeth A Barrett, Jason Drew Smith, Mark Schoenberg, Molly Henderson, Peter P Pfreundschuh and Stephen Mullennix.
View institutional ownership trends
.

How do I buy shares of UroGen Pharma?

Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is UroGen Pharma's stock price today?

One share of URGN stock can currently be purchased for approximately $8.53.

How much money does UroGen Pharma make?

UroGen Pharma (NASDAQ:URGN) has a market capitalization of $178.28 million and generates $48.04 million in revenue each year. The company earns $-110,820,000.00 in net income (profit) each year or ($5.04) on an earnings per share basis.

How many employees does UroGen Pharma have?

The company employs 195 workers across the globe.

How can I contact UroGen Pharma?

UroGen Pharma's mailing address is 400 Alexander Park, Princeton NJ, 08540. The official website for the company is www.urogen.com. The company can be reached via phone at (646) 768-9780 or via email at kate.bechtold@urogen.com.

This page (NASDAQ:URGN) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.